Generic Biosimilar Medicines Association

Making Medicines Affordable

  • Home
  • About GBMA
    • Contact us
    • GBMA Members
    • Guiding principles
    • Code of Practice
      • Code Complaint Committee
      • Event Reporting
        • Educational Events
        • Non-Price Benefit Reports
      • Annual Review
        • 2011
        • 2012
        • 2013
        • 2014
        • 2015
        • 2016
        • 2017
        • 2018
        • 2019
        • 2020
      • Lodging a complaint
    • Media Enquiries
    • Our Objectives
    • Links
  • Advocacy
    • Extended Strategic Agreement
    • Generic Medicines Working Group (GMWG)
    • Submissions
  • Generics
    • Facts and Fallacies
    • Key Figures on Generic Medicines
    • What is a Generic Medicine?
    • Bioequivalence Explained
  • Biosimilars
    • IGBA Global Biosimilars Week
    • GBMA Position on Biosimilars
      • Impact of Biosimilars
      • Switching
      • Pharmacy Substitution
      • Regulation
      • Awareness and Uptake
      • Naming
    • Key Figures on Biosimilars
  • Topics
    • IGBA
    • Price Disclosure
    • Intellectual Property
    • International Trade Agreements
  • News
    • News 2021
    • News 2020
    • News 2019
    • News 2018
    • News 2017
    • News 2016
    • News 2015
    • News 2014
  • GBMA Education
  • COVID-19 Virus
    • COVID-19 Virus: The Facts
You are here: Home / GBMA Code of Practice / Annual Review / 2012

2012

The Generic Medicines Industry Association (GMiA) is pleased to announce the completion of its Code of Practice review for 2012.   The review indicates that the Code has been effective in formalising the high standards of conduct adhered to by its Members.

Pursuant to section 15 of the Code, the Code Administration Committee was convened in October 2012 to ensure the successful implementation and ongoing effectiveness of the Code. The Committee prepared its annual report for the GMiA Board. This report is posted below.

 

imagesCANP5FVD

GMiA Code of Practice Review October 2012

 

As set out in section 13 of the Code, an Independent Reviewer has reviewed the Educational Event Reports submitted by Members and conducted spot audits of Members’ marketing and promotional material to determine compliance with the Code.  The Independent Reviewer concluded that there was nothing to indicate any level of non-compliance by Members. The Independent Reviewer’s report is posted below.

 

imagesCANP5FVD

 

Final Independent Review Report 2012

Our Members

Juno
Juno
Sandoz logo
Sandoz logo
Viatris
Viatris
Arrow logo
Arrow logo
apotex
apotex
Celltrion Healthcare
Celltrion Healthcare
Fresnius Kabi
Fresnius Kabi
Fresnius Kabi
generic_partners
generic_partners
southern_cross
southern_cross
commercial_eyes
commercial_eyes
sinapse
sinapse

Generic Medicines: The Facts

Generic Medicines Facts

Generic medicines are quality medicines at affordable prices. Ask your doctor to prescribe a generic medicine, or ask for a generic medicine next time you take your prescription to the pharmacy. … More…

The promise of Biosimilars

Biosimilars

https://youtu.be/sBDur7xa084   Biosimilars provide a unique opportunity to help manage the growing costs of biological medicines on the PBS. They offer therapeutically equivalent and … More…

Patients and economy to benefit from ‘medicine manufacturing’ roadmap

March 2, 2021

2 March 2021 Canberra, ACT Australia’s peak body for affordable medicines, today welcomed the Government’s launch of … More...

Active Ingredient Prescribing – a game changer for patients: Prescription reforms to further support patient safety

February 1, 2021

1 February 2021 Canberra, ACT Canberra: Australia’s patients will be the … More...

Announcement of Independent Chair

December 9, 2020

9 December 2020 Canberra, ACT Global health policy powerhouse, Jane Halton … More…

© 2021 Generic Medicines Industry Association Pty Ltd | Site Map | Contact Us